Rajendra Singh

About Rajendra Singh

Pathology has always been fundamental to clinical decision-making, influencing over 70% of healthcare interventions. Despite this, it often remains an underappreciated specialty. Pathologists are frequently isolated from strategic leadership and largely absent from broader innovation discussions. As healthcare increasingly moves towards a data-driven, personalized, and AI-augmented future, pathology is uniquely positioned to drive this transformation.

Repositioning pathology from a support service to a central driver of innovation has been the core purpose of my career.

Over the past three decades, I have held academic leadership roles at various academic centers and private groups. I’ve always embraced a dual identity: a full-time practicing pathologist dedicated to diagnostic excellence, and an entrepreneur driven by the conviction that technology and innovation are essential to advancing our field and serving clinicians and patients more effectively.

This passion led me to develop tools initially focused on democratizing access to knowledge. I launched MyDermPath, which became the most downloaded dermatopathology education app. Subsequently, I founded PathPresenter, a digital platform that revolutionized how pathology is taught, learned, and practiced worldwide. During the COVID-19 pandemic, it became a vital resource for pathology departments, enabling virtual education and training when in-person learning ceased. Today it provides free access to 30,000 plus WSI to 65,000 users in more than 170 countries for learning and teaching pathology.

My work extended beyond education to transforming core workflows. In collaboration with the WHO, I helped digitize the iconic WHO Classification of Tumors (the “Blue Books”), making them globally accessible in interactive formats. Through partnerships with institutions like OUSMC, and regulatory agencies such as FDA, we developed platforms for securely sharing pathology data across institutions, facilitating collaborative research, consultations, and second opinions.

As these efforts progressed, one critical need became clear: for pathology to become truly multi-modal and technology-enabled, interoperability and standardization of image data were paramount. In response, I spearheaded the development of the PathPresenter IMS, a next-generation FDA-approved IMS built with proprietary HL7 engines and AI middleware. This infrastructure enables seamless integration with hospital IT systems and simplifies the deployment of AI models within real-world clinical environments.

To further accelerate the adoption of AI, I collaborated with the CAP to launch the CAP AI Playground—a pioneering platform that allows pathologists to easily explore, evaluate, and interact with AI models. This empowers pathologists to move beyond diagnosis, offering prognostic and therapeutic insights that directly influence clinical decision-making and patient outcomes.

The most exciting developments in pathology are still ahead. With the emergence of generative AI and advanced computational platforms, we are entering an era where pathology can not only diagnose—it can predict, personalize, and even guide therapeutic decisions in real time. With each innovation, we move closer to repositioning our field as the true engine of modern healthcare—where diagnostic excellence, prognostic clarity, and personalized care converge to shape a healthier future. My mission remains clear: to build the tools and ecosystems that transform potential into progress, and ensure that pathology leads—not follows—in this next chapter of medicine.